RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, L?kahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and advanced five into active company discussions. These assets represent more than $500 million in prior biopharmaceutical investment and include oppor
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
